Latest Headlines

Latest Headlines

Sanofi in talks to buy Indian OTC business

Sanofi ($SNY) is in the throes of another emerging markets deal. The French drugmaker's Indian unit Aventis Pharma is talking to buy the over-the-counter business of Universal Medicare. At about 5

Survey: Lipitor, Plavix yield best heart-patient outcomes

The results of a survey of cardiologists could provoke tears from executives at Pfizer ($PFE), Sanofi ($SNY) and Bristol-Myers Squibb ($BMY). Tears of happiness, maybe--Pfizer's Lipitor and the

Chattem's Allegra success buoys Sanofi diversification

For a data point on diversification, look no further than Sanofi's ($SNY) new Chattem unit. The French drugmaker snapped up U.S.-based Chattem to fortify its consumer healthcare business, and chief

Genzyme boosts Sanofi forecast, but falls short on CVR

Sanofi's second-quarter chatter is all about Genzyme. Earnings forecasts are up, for instance, thanks to the inclusion of Genzyme numbers for the first time. Troublesome generics competition for some

FDA joins Multaq review, reveals prelim study data

FDA has joined the Multaq review effort. The agency said that it is analyzing data from the recently halted trial of Multaq in patients with permanent atrial fibrillation. Sanofi stopped that

Valeant aims for top of dermatology, CEO says

No, you don't have double vision. Valeant Pharmaceuticals ($VRX) did buy two dermatology operations last week. First came Sanofi's ($SNY) Dermik unit, which Valeant agreed to acquire for $425

EMA broadens safety review on Sanofi's Multaq

It's not shaping up to be a great week for Sanofi ($SNY). Yesterday, the company announced that its multiple sclerosis drug candidate Lemtrada didn't meet its secondary endpoint in a clinical trial,

Valeant snaps up Sanofi's Dermik for $425M

Sanofi ($SNY) has agreed to offload its Dermik skincare business to Valeant Pharmaceuticals ($VRX) in a $425 million deal that gives the Canadian drugmaker brands such as the acne treatment BenzaClin

Sanofi's Multaq takes hit from trial failure

Sanofi's ($SNY) Multaq has stumbled again. The company stopped a trial of the atrial fibrillation drug in patients with a permanent version of AF after researchers flagged some serious cardiovascular

Congress pushes 10 drugmakers for heparin info

Unsatisfied with the information it has drawn from the FDA, a congressional committee is broadening its probe into the years-old heparin contamination scandal. The House Energy and Commerce Committee